Skip to main content
Erschienen in: Arthritis Research & Therapy 4/2005

01.09.2005 | Review

Balancing the gastrointestinal benefits and risks of nonselective NSAIDs

verfasst von: David A Peura, Lawrence Goldkind

Erschienen in: Arthritis Research & Therapy | Sonderheft 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used classes of medications to treat pain and inflammation. However, gastrointestinal complications associated with NSAIDs are prevalent, largely due to the frequent use of these agents. Adverse events associated with NSAIDs include minor side effects, such as dyspepsia, as well as serious complications, such as bleeding and perforation. Although the probability that any given individual user of an NSAID will suffer a serious gastrointestinal complication is fairly low, widespread patient exposure can translate into a major national health burden. The increasing use of aspirin in the prevention of cardiovascular events and the availability of select over-the-counter NSAIDs represent additional challenges to clinicians in their efforts to make the most appropriate therapeutic decisions while minimizing the potential gastrointestinal risks associated with the use of these agents. Side effects such as dyspepsia do not provide adequate warning of gastrointestinal complications, because most complications occur without the presence of antecedent symptoms. Therefore, accurate risk assessment and the management of controllable risk factors are crucial to the safe administration of NSAIDs. This review focuses on the gastrointestinal effects of aspirin, acetaminophen, and other nonselective NSAIDs, and discusses those factors that are associated with increased risk for adverse gastrointestinal events in certain individuals.
Literatur
1.
Zurück zum Zitat Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA: Toward an epidemiology of gastropathy associated with non-steroidal antiinflammatory drug use. Gastroenterology. 1989, 647-655. Suppl Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA: Toward an epidemiology of gastropathy associated with non-steroidal antiinflammatory drug use. Gastroenterology. 1989, 647-655. Suppl
2.
Zurück zum Zitat Rahme E, Marentette MA, Kong SX, Lelorier J: Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated copre-scriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 2002, 47: 595-602. 10.1002/art.10796.CrossRefPubMed Rahme E, Marentette MA, Kong SX, Lelorier J: Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated copre-scriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 2002, 47: 595-602. 10.1002/art.10796.CrossRefPubMed
3.
Zurück zum Zitat Abramson SB, Weaver AL: Current state of therapy for pain and inflammation. Arthritis Research & Therapy. 2005, 7 (suppl 4): S1-S6.CrossRef Abramson SB, Weaver AL: Current state of therapy for pain and inflammation. Arthritis Research & Therapy. 2005, 7 (suppl 4): S1-S6.CrossRef
4.
Zurück zum Zitat Dubois RW, Melmed GY, Henning JM, Laine L: Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004, 19: 197-208. 10.1111/j.0269-2813.2004.01834.x.CrossRefPubMed Dubois RW, Melmed GY, Henning JM, Laine L: Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004, 19: 197-208. 10.1111/j.0269-2813.2004.01834.x.CrossRefPubMed
5.
Zurück zum Zitat Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991, 115: 787-796.CrossRefPubMed Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991, 115: 787-796.CrossRefPubMed
6.
Zurück zum Zitat Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999, 18-24. Suppl 56 Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999, 18-24. Suppl 56
7.
Zurück zum Zitat Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001, 120: 594-606. 10.1053/gast.2001.21907.CrossRefPubMed Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001, 120: 594-606. 10.1053/gast.2001.21907.CrossRefPubMed
8.
Zurück zum Zitat Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995, 123: 241-249.CrossRefPubMed Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995, 123: 241-249.CrossRefPubMed
9.
Zurück zum Zitat Coles LS, Fries JF, Kraines RG, Roth SH: From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983, 74: 820-828. 10.1016/0002-9343(83)91073-2.CrossRefPubMed Coles LS, Fries JF, Kraines RG, Roth SH: From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983, 74: 820-828. 10.1016/0002-9343(83)91073-2.CrossRefPubMed
10.
Zurück zum Zitat Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA. 2000, 284: 1247-1255. 10.1001/jama.284.10.1247.CrossRefPubMed Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA. 2000, 284: 1247-1255. 10.1001/jama.284.10.1247.CrossRefPubMed
11.
Zurück zum Zitat Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103.CrossRefPubMed Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103.CrossRefPubMed
12.
Zurück zum Zitat Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B: The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 2433-2440. 10.1002/art.20440.CrossRefPubMed Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B: The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 2433-2440. 10.1002/art.20440.CrossRefPubMed
13.
Zurück zum Zitat Cryer B: Nonsteroidal antiinflammatory drugs and gastrointestinal disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Edited by: Feldman M, Scharschmidt BF, Sleisenger M. 1998, Philadelphia, PA: WB Saunders Co, 343-357. Cryer B: Nonsteroidal antiinflammatory drugs and gastrointestinal disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Edited by: Feldman M, Scharschmidt BF, Sleisenger M. 1998, Philadelphia, PA: WB Saunders Co, 343-357.
14.
Zurück zum Zitat Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ: Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995, 40: 1345-1350. 10.1007/BF02065549.CrossRefPubMed Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ: Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995, 40: 1345-1350. 10.1007/BF02065549.CrossRefPubMed
15.
Zurück zum Zitat Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002, 359: 14-22. 10.1016/S0140-6736(02)07273-2.CrossRefPubMed Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002, 359: 14-22. 10.1016/S0140-6736(02)07273-2.CrossRefPubMed
16.
Zurück zum Zitat Scheiman JM: NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996, 25: 279-298. 10.1016/S0889-8553(05)70247-8.CrossRefPubMed Scheiman JM: NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996, 25: 279-298. 10.1016/S0889-8553(05)70247-8.CrossRefPubMed
17.
Zurück zum Zitat Scheiman JM: Effects of nonsteroidal antiinflammatory drugs, including COX-2 specific inhibitors, on the GI tract. Clinical update. Am Soc Gastrointest Endosc. 2005, 13: 1-4. Scheiman JM: Effects of nonsteroidal antiinflammatory drugs, including COX-2 specific inhibitors, on the GI tract. Clinical update. Am Soc Gastrointest Endosc. 2005, 13: 1-4.
18.
Zurück zum Zitat American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002, 46: 328-346. 10.1002/art.10148.CrossRef American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002, 46: 328-346. 10.1002/art.10148.CrossRef
19.
Zurück zum Zitat Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994, 343: 769-772. 10.1016/S0140-6736(94)91843-0.CrossRefPubMed Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994, 343: 769-772. 10.1016/S0140-6736(94)91843-0.CrossRefPubMed
20.
Zurück zum Zitat Singh G: Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000, 7: 115-121.CrossRefPubMed Singh G: Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000, 7: 115-121.CrossRefPubMed
21.
Zurück zum Zitat Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF: Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996, 156: 1530-1536. 10.1001/archinte.156.14.1530.CrossRefPubMed Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF: Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996, 156: 1530-1536. 10.1001/archinte.156.14.1530.CrossRefPubMed
22.
Zurück zum Zitat Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM: Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther. 2001, 15: 63-71. 10.1046/j.1365-2036.2001.00874.x.CrossRefPubMed Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM: Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther. 2001, 15: 63-71. 10.1046/j.1365-2036.2001.00874.x.CrossRefPubMed
23.
Zurück zum Zitat Peura D: The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol. 2000, 14: 109-117. 10.1053/bega.1999.0062.CrossRefPubMed Peura D: The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol. 2000, 14: 109-117. 10.1053/bega.1999.0062.CrossRefPubMed
24.
Zurück zum Zitat Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, et al: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001, 344: 967-973. 10.1056/NEJM200103293441304.CrossRefPubMed Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, et al: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001, 344: 967-973. 10.1056/NEJM200103293441304.CrossRefPubMed
25.
Zurück zum Zitat Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996, 312: 1563-1566.PubMedCentralCrossRefPubMed Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996, 312: 1563-1566.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Garcia Rodriguez LA, Hernandez-Diaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004, 159: 23-31. 10.1093/aje/kwh005.CrossRefPubMed Garcia Rodriguez LA, Hernandez-Diaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004, 159: 23-31. 10.1093/aje/kwh005.CrossRefPubMed
27.
Zurück zum Zitat Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003, 163: 2006-2010. 10.1001/archinte.163.17.2006.CrossRefPubMed Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003, 163: 2006-2010. 10.1001/archinte.163.17.2006.CrossRefPubMed
28.
Zurück zum Zitat Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, et al: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002, 106: 388-391. 10.1161/01.CIR.0000020190.45892.75.CrossRefPubMed Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, et al: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002, 106: 388-391. 10.1161/01.CIR.0000020190.45892.75.CrossRefPubMed
29.
Zurück zum Zitat Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S: Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med. 1988, 148: 281-285. 10.1001/archinte.148.2.281.CrossRefPubMed Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S: Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med. 1988, 148: 281-285. 10.1001/archinte.148.2.281.CrossRefPubMed
30.
Zurück zum Zitat Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000, 95: 2218-2224. 10.1016/S0002-9270(00)01040-6.CrossRefPubMed Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000, 95: 2218-2224. 10.1016/S0002-9270(00)01040-6.CrossRefPubMed
31.
Zurück zum Zitat Laine L: Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary?. Rev Gastroenterol Disord. 2004, S33-S41. Suppl 4 Laine L: Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary?. Rev Gastroenterol Disord. 2004, S33-S41. Suppl 4
32.
Zurück zum Zitat Garcia Rodriguez LA, Hernandez-Diaz S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001, 12: 570-576. 10.1097/00001648-200109000-00018.CrossRefPubMed Garcia Rodriguez LA, Hernandez-Diaz S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001, 12: 570-576. 10.1097/00001648-200109000-00018.CrossRefPubMed
33.
Zurück zum Zitat Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999, 96: 7563-7568. 10.1073/pnas.96.13.7563.PubMedCentralCrossRefPubMed Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999, 96: 7563-7568. 10.1073/pnas.96.13.7563.PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum. 1995, 38: 1541-1546.CrossRefPubMed Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum. 1995, 38: 1541-1546.CrossRefPubMed
35.
Zurück zum Zitat Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum. 1995, 38: 1535-1540.CrossRefPubMed Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum. 1995, 38: 1535-1540.CrossRefPubMed
36.
Zurück zum Zitat Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, et al: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004, 63: 931-939. 10.1136/ard.2003.020313.PubMedCentralCrossRefPubMed Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, et al: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004, 63: 931-939. 10.1136/ard.2003.020313.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med. 2003, 163: 169-178. 10.1001/archinte.163.2.169.CrossRefPubMed Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med. 2003, 163: 169-178. 10.1001/archinte.163.2.169.CrossRefPubMed
38.
Zurück zum Zitat Wolfe F, Zhao S, Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000, 43: 378-385. 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2.CrossRefPubMed Wolfe F, Zhao S, Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000, 43: 378-385. 10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2.CrossRefPubMed
39.
Zurück zum Zitat Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ: A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004, 51: 746-754. 10.1002/art.20698.CrossRefPubMed Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ: A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004, 51: 746-754. 10.1002/art.20698.CrossRefPubMed
40.
Zurück zum Zitat Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004, 63: 901-907. 10.1136/ard.2003.018531.PubMedCentralCrossRefPubMed Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004, 63: 901-907. 10.1136/ard.2003.018531.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H: Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994, 154: 311-316. 10.1001/archinte.154.3.311.CrossRefPubMed Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H: Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994, 154: 311-316. 10.1001/archinte.154.3.311.CrossRefPubMed
42.
Zurück zum Zitat Carson JL, Strom BL, Duff A, Gupta A, Das K: Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med. 1993, 153: 1331-1336. 10.1001/archinte.153.11.1331.CrossRefPubMed Carson JL, Strom BL, Duff A, Gupta A, Das K: Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med. 1993, 153: 1331-1336. 10.1001/archinte.153.11.1331.CrossRefPubMed
43.
44.
Zurück zum Zitat Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil OA, Hay JE, Hynan L, U.S. Acute Liver Failure Study Group, et al: Results of a prospective study of acute liver failure at 17 teriary care centers in the United States. Ann Intern Med. 2002, 137: 947-954.CrossRefPubMed Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil OA, Hay JE, Hynan L, U.S. Acute Liver Failure Study Group, et al: Results of a prospective study of acute liver failure at 17 teriary care centers in the United States. Ann Intern Med. 2002, 137: 947-954.CrossRefPubMed
47.
Zurück zum Zitat Borer JS, Simon LE: Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Research & Therapy. 2005, 7 (suppl 4): S14-S22.CrossRef Borer JS, Simon LE: Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Research & Therapy. 2005, 7 (suppl 4): S14-S22.CrossRef
48.
Zurück zum Zitat Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG, the Arthrotec Osteoarthritis Study Group: Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol. 1998, 25: 1602-1611.PubMed Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG, the Arthrotec Osteoarthritis Study Group: Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol. 1998, 25: 1602-1611.PubMed
49.
Zurück zum Zitat Graham DY, White RH, Moreland LW, the Misoprostol Study Group: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993, 119: 257-262.CrossRefPubMed Graham DY, White RH, Moreland LW, the Misoprostol Study Group: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993, 119: 257-262.CrossRefPubMed
50.
Zurück zum Zitat Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ: Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998, 12: 135-140. 10.1046/j.1365-2036.1998.00288.x.CrossRefPubMed Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ: Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998, 12: 135-140. 10.1046/j.1365-2036.1998.00288.x.CrossRefPubMed
51.
Zurück zum Zitat Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND, the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998, 338: 727-734. 10.1056/NEJM199803123381105.CrossRefPubMed Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND, the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998, 338: 727-734. 10.1056/NEJM199803123381105.CrossRefPubMed
52.
Zurück zum Zitat Lanas A, Rodrigo L, Marquez J, Bajador E, Perez-Roldan F, Cabrol J, Quintero E, Montoro M, Gomollon F, Santolaria S, EMPHASYS Study Group, et al: Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003, 38: 693-700. 10.1080/00365520310003967.CrossRefPubMed Lanas A, Rodrigo L, Marquez J, Bajador E, Perez-Roldan F, Cabrol J, Quintero E, Montoro M, Gomollon F, Santolaria S, EMPHASYS Study Group, et al: Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003, 38: 693-700. 10.1080/00365520310003967.CrossRefPubMed
53.
Zurück zum Zitat Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, Leung WK, Lee YT, To KF, Chung SC, et al: Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004, 127: 1038-1043. 10.1053/j.gastro.2004.07.010.CrossRefPubMed Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, Leung WK, Lee YT, To KF, Chung SC, et al: Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004, 127: 1038-1043. 10.1053/j.gastro.2004.07.010.CrossRefPubMed
54.
Zurück zum Zitat Scheiman JM, Fendrick AM: Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Research & Therapy. 2005, 7 (suppl 4): S23-S29.CrossRef Scheiman JM, Fendrick AM: Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Research & Therapy. 2005, 7 (suppl 4): S23-S29.CrossRef
Metadaten
Titel
Balancing the gastrointestinal benefits and risks of nonselective NSAIDs
verfasst von
David A Peura
Lawrence Goldkind
Publikationsdatum
01.09.2005
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe Sonderheft 4/2005
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1793

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.